Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07718295

HFNO Versus Face Mask for Cerebral Oxygenation During Procedural Sedation

This prospective randomized controlled trial aims to compare the effects of high-flow nasal oxygen (HFNO) and conventional face mask oxygen therapy on cerebral oxygenation during procedural sedation performed outside the operating room. Adult patients undergoing elective diagnostic or interventional procedures under procedural sedation will be randomly assigned to receive either HFNO or conventional face mask oxygen. Regional cerebral oxygen saturation will be continuously monitored using near-infrared spectroscopy (NIRS), while sedation depth will be assessed using the Patient State Index (PSI, SedLine) and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale. Secondary outcomes include peripheral oxygenation, ventilation parameters, arterial blood gas values, airway interventions, hemodynamic variables, and patient and practitioner satisfaction.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fırat University Faculty of Medicine Hospital

Elâzığ, 23100, Turkey (Türkiye)

Location status: Recruiting

Location contact

Ahmet Aksu, Assistant Professor

CONTACT

[email protected]

+905303493896 ext. +904242333555

Ahmet Demirdağ, Assistant Professor

CONTACT

[email protected]

+905427158774

Ahmet Demirdağ, Assistant Professor

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older
  • American Society of Anesthesiologists physical status I-IV
  • Scheduled for an elective diagnostic or interventional procedure performed under procedural sedation in a non-operating-room setting
  • Ability to provide written informed consent
  • Willingness to participate in the study

Exclusion criteria

  • Age younger than 18 years
  • Refusal or inability to provide written informed consent
  • Known neurological disorders
  • History of ischemic or hemorrhagic stroke
  • History of traumatic brain injury or previous cranial surgery
  • Peripheral arterial disease or systemic vasculitis
  • Advanced heart failure
  • Uncontrolled hypertension
  • Uncontrolled diabetes mellitus
  • Advanced chronic obstructive pulmonary disease (COPD)
  • Severe anemia (hemoglobin <8 g/dL)
  • Skin lesions or other conditions preventing proper placement of NIRS sensors
  • Nasal deformity or nasal obstruction preventing the use of high-flow nasal oxygen therapy
  • Any condition that, in the opinion of the investigators, could interfere with study participation or the interpretation of study results

Treatment and study plan

High-Flow Nasal Oxygen (HFNO)

Device

Participants receive heated humidified high-flow nasal oxygen during procedural sedation.

Conventional Face Mask Oxygen

Device

Oxygen administered through a conventional face mask at 6 L/min with an approximate FiO₂ of 40%.

Primary outcomes

  1. Change in Regional Cerebral Oxygen Saturation (ΔrSO₂)

    Time frame: From initiation of procedural sedation until completion of the procedure (up to approximately 120 minutes).

    The change in regional cerebral oxygen saturation (rSO₂) measured by near-infrared spectroscopy (NIRS), calculated as the difference between the mean intra-procedural rSO₂ and the baseline value.

Secondary outcomes

  1. Peripheral Oxygen Saturation (SpO₂)

    Time frame: From baseline to completion of procedural sedation (up to approximately 120 minutes).

  2. End-Tidal Carbon Dioxide (EtCO₂)

    Time frame: Baseline and at completion of the procedure.

  3. Arterial Oxygen Tension (PaO₂)

    Time frame: Before sedation and immediately after completion of the procedure.

  4. Arterial Carbon Dioxide Tension (PaCO₂)

    Time frame: Before sedation and immediately after completion of the procedure.

  5. Incidence of Hypoxemia

    Time frame: During procedural sedation (up to approximately 120 minutes).

    Peripheral oxygen saturation <90% lasting at least 10 seconds.

  6. Number of Participants with a ≥20% Decrease in Regional Cerebral Oxygen Saturation (rSO₂) from Baseline

    Time frame: During procedural sedation (up to approximately 120 minutes).

    Number of participants who experience a decrease in regional cerebral oxygen saturation (rSO₂) of 20% or more from the baseline value during procedural sedation.

  7. Number of Participants Requiring Airway Intervention During Procedural Sedation

    Time frame: During procedural sedation.

    Number of participants requiring any airway intervention, including chin lift, jaw thrust, mask ventilation, supraglottic airway placement, or endotracheal intubation during procedural sedation.

  8. Patient State Index (PSI) During Procedural Sedation

    Time frame: Throughout procedural sedation until completion of the procedure.

    Mean Patient State Index (PSI) recorded throughout procedural sedation. The PSI ranges from 0 to 100, with lower values indicating deeper levels of sedation.

  9. Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score During Procedural Sedation

    Time frame: Throughout procedural sedation until completion of the procedure.

    Mean Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score recorded during procedural sedation. Scores range from 0 to 5, where lower scores indicate deeper sedation and higher scores indicate greater alertness.

  10. Heart Rate During Procedural Sedation

    Time frame: From baseline until completion of the procedure.

    Mean heart rate (beats per minute) recorded from baseline until completion of the procedure.

  11. Mean Arterial Pressure During Procedural Sedation

    Time frame: Throughout procedural sedation until completion of the procedure.

    Mean non-invasive arterial blood pressure (mmHg) recorded from baseline until completion of the procedure.

  12. Sedative Drug Consumption

    Time frame: During procedural sedation.

    Total doses of propofol, remifentanil, and midazolam.

  13. Patient Satisfaction Score Using a 5-Point Likert Scale

    Time frame: Immediately after recovery from procedural sedation.

    Patient satisfaction was assessed immediately after recovery using a 5-point Likert scale (1 = very dissatisfied, 5 = very satisfied). Higher scores indicate greater satisfaction.

  14. Practitioner Satisfaction Score Using a 5-Point Likert Scale

    Time frame: Immediately after completion of the procedure.

    Practitioner satisfaction with the procedure was assessed immediately after completion using a 5-point Likert scale (1 = very dissatisfied, 5 = very satisfied). Higher scores indicate greater satisfaction.

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmet Aksu, Assistant Professor

CONTACT

[email protected]

+905303493896

Sponsors and collaborators

Lead sponsor

Firat University

Other

Registry information

Official study title

Effects of High-Flow Nasal Oxygen Versus Conventional Face Mask Oxygen on Cerebral Oxygenation During Out-of-Operating-Room Procedural Sedation: A Prospective Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 21, 2026
Registry last updated
Jul 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.